Abstract
Giant cell tumour of bone (GCTB) is a primary tumour of bone that may rarely, in the absence of malignant cytological features, produce metastatic lesions, most commonly in the lungs. Whether these lung nodules represent true neoplastic secondaries or implants derived from the primary tumour is not certain. In this study, we have analysed the morphological and immunophenotypic features of 19 conventional GCTBs and corresponding lung nodules for expression of macrophage, osteoclast, proliferation and tumour-associated markers. A striking morphological feature of all GCTBs that produced lung secondaries was the presence of large areas of haemorrhage and thrombus formation; mononuclear and multinucleated cells of GCTB were frequently found within these areas of haemorrhage and thrombus. A similar pattern of CD14, CD33, HLA-DR and CD51 expression was seen in macrophages and giant cells in primary and secondary tumours. Smooth muscle actin expression was frequently noted in primary GCTBs that recurred and metastasised. No difference was seen in the expression of p53, p63, Ki-67, cyclin D1 or Bcl-2 in primary and secondary tumours. Our findings suggest that most lung nodules associated with primary conventional GCTBs are implants derived from tumour emboli formed in areas of haemorrhage and thrombus formation within the primary tumour.
Similar content being viewed by others
References
Reid R, Bareyce SS, Sciot R (2002) Giant cell tumour. In: Fletcher C, Unni K, Mertens F (eds) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 310–312
Unni K, Inwards C, Bridge J et al (2005) Tumours of the bones and joints. AFIP Atlas of Tumour Pathology Fourth Series, AFIP, pp 281–298
Geshickter CF, Copeland MM (1930) Recurrent and so-called metastatic giant cell tumour. Arch Surg 20(5):714–755
Turcotte RE (2006) Giant cell tumour of bone. Orthop Clin N Am 32:35–51
Bertoni F, Present D, Sudanese A et al (1988) Giant cell tumour of bone with pulmonary metastases. Clin Orthop 237:275–285
Rock MG, Pritchard DJ, Unni KK (1984) Metastases from histologically benign giant-cell tumour of bone. J Bone Joint Surg 66N:269–273
Tubbs WS, Brown LR, Beabout JW et al (1992) Benign giant-cell tumour of bone with pulmonary metastases. AJR 158:331–334
Faisham WI, Zulmi W, Saim AH et al (2004) Pulmonary metastases of giant cell tumour of the bone. Med J Malaysia 59(Suppl F):78–81
Maloney WJ, Vaughan LM, Jones HH et al (1989) Benign metastasizing giant cell tumour of bone. Clin Orthop 243:208–215
Huvos AG (1991) Bone tumours: diagnosis, treatment and prognosis. Saunders, Philadelphia, pp 429–467
Mirra JM, Ulich T, Magidson J et al (1982) A case of probable benign pulmonary “metastases” or implants arising from a giant cell tumour of bone. Clin Orthop 162:245–254
Forsyth RG, De Boeck G, Baeide JJ et al (2009) CD33+ CD14− phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumour of bone. J Bone Miner Res 24:70–77
Lau YS, Sabokbar A, Gibbons CL et al (2005) Phenotypic and molecular studies of giant-cell tumours of bone and soft tissue. Hum Pathol 36:945–954
Bertoni F, Present D, Enneking WF (1985) Giant-cell tumour of bone with pulmonary metastases. J Bone Joint Surg 67A:890–900
Forest M (1988) Orthopaedic surgical pathology: diagnosis of tumours and pseudotumoral lesions of bone and joint. Churchill Livingstone, New York, pp 423–428
Dickson BC, Li SQ, Wunder JS et al (2008) Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumour of the bone. Mod Pathol 21:531–539
Ladanyi M, Traganos F, Huvos AG (1989) Benign metastasizing giant cell tumours of bone. A DNA flow cytometric study. Cancer 64:1521–1526
Osaka S, Toriyama M, Taira K et al (1997) Analysis of giant cell tumour of bone with pulmonary metastases. Clin Orthop 335:253–261
Osaka S, Sugita H, Osaka E et al (2004) Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series. Orthop Surg 12:55–62
Forsyth RG, De Boeck G, Bekaert S et al (2008) Telomere biology in giant cell tumour of bone. J Pathol 214:555–563
de Souza PE, Paim JF, Carvalhais JN et al (1999) Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumour. J Oral Pathol Med 28:54–58
Ueda Y, Dockhorn-Dworniczak B, Blasius S et al (1993) Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119:172–178
Rao UN, Goodman M, Chung WW et al (2005) Molecular analysis of primary and recurrent giant cell tumours of bone. Cancer Genet Cytogenet 158:126–136
Masui F, Ushigome S, Fujii K (1998) Giant cell tumour of bone: a clinicopathologic study of prognostic factors. Pathol Int 48:723–729
Sulh MA, Greco MA, Jiang T et al (1996) Proliferation index and vascular density of giant cell tumours of bone: are they prognostic markers? Cancer 77:2044–2051
Lindeman JH, Hanemaaijer R, Mulder A et al (2004) Cathepsin K is the principal protease in giant cell tumour of bone. Am J Pathol 165:593–600
Acknowledgement
The authors are members of EuroBoNet, a European Network of Excellence studying the pathology and genetics of bone tumours. The authors thank Chris Lowe for typing the manuscript.
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alberghini, M., Kliskey, K., Krenacs, T. et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 456, 97–103 (2010). https://doi.org/10.1007/s00428-009-0863-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-009-0863-2